• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Patterns and predictors of amelioration of genitourinary toxicity after high-dose intensity-modulated radiation therapy for localized prostate cancer: implications for defining postradiotherapy urinary toxicity.高强度调强放疗治疗局限性前列腺癌后泌尿生殖毒性改善的模式和预测因素:对定义放疗后尿毒性的影响。
Eur Urol. 2013 Dec;64(6):931-8. doi: 10.1016/j.eururo.2013.02.001. Epub 2013 Feb 14.
2
Improved toxicity profile following high-dose postprostatectomy salvage radiation therapy with intensity-modulated radiation therapy.高强度聚焦超声治疗子宫肌瘤的疗效及安全性:一项多中心、随机对照临床试验
Eur Urol. 2011 Dec;60(6):1142-8. doi: 10.1016/j.eururo.2011.08.006. Epub 2011 Aug 12.
3
A case-matched study of toxicity outcomes after proton therapy and intensity-modulated radiation therapy for prostate cancer.一项关于前列腺癌质子治疗和调强放射治疗后毒性结果的病例对照研究。
Cancer. 2015 Apr 1;121(7):1118-27. doi: 10.1002/cncr.29148. Epub 2014 Nov 25.
4
Impact of dose to the bladder trigone on long-term urinary function after high-dose intensity modulated radiation therapy for localized prostate cancer.高剂量强度调制放疗局部前列腺癌后三角区膀胱剂量对长期尿功能的影响。
Int J Radiat Oncol Biol Phys. 2014 Feb 1;88(2):339-44. doi: 10.1016/j.ijrobp.2013.10.042.
5
Patient-reported Outcomes and Late Toxicity After Postprostatectomy Intensity-modulated Radiation Therapy.前列腺癌根治术后调强放疗的患者报告结局和晚期毒性。
Eur Urol. 2019 Nov;76(5):686-692. doi: 10.1016/j.eururo.2019.05.011. Epub 2019 May 19.
6
Early and late side effects, dosimetric parameters and quality of life after proton beam therapy and IMRT for prostate cancer: a matched-pair analysis.质子束治疗和调强放射治疗前列腺癌的早晚期副作用、剂量学参数和生活质量:配对分析。
Acta Oncol. 2019 Jun;58(6):916-925. doi: 10.1080/0284186X.2019.1581373. Epub 2019 Mar 18.
7
Initial report of the genitourinary and gastrointestinal toxicity of post-prostatectomy proton therapy for prostate cancer patients undergoing adjuvant or salvage radiotherapy.前列腺癌患者接受辅助或挽救性放疗后前列腺切除术后质子治疗的泌尿生殖和胃肠道毒性的初步报告。
Acta Oncol. 2018 Nov;57(11):1506-1514. doi: 10.1080/0284186X.2018.1487583. Epub 2018 Jul 20.
8
Late toxicity after intensity-modulated radiation therapy for localized prostate cancer: an exploration of dose-volume histogram parameters to limit genitourinary and gastrointestinal toxicity.局限性前列腺癌调强放疗后的晚期毒性:探索剂量-体积直方图参数以限制泌尿生殖系统和胃肠道毒性。
Int J Radiat Oncol Biol Phys. 2012 Jan 1;82(1):235-41. doi: 10.1016/j.ijrobp.2010.09.058. Epub 2010 Dec 14.
9
Urinary toxicity after high dose intensity modulated radiotherapy as primary therapy for prostate cancer.高剂量调强放疗作为前列腺癌主要治疗手段后的泌尿毒性
Radiother Oncol. 2009 Jul;92(1):42-7. doi: 10.1016/j.radonc.2009.03.013. Epub 2009 Apr 6.
10
Risk adapted dose-intensified postoperative radiation therapy in prostate cancer patients using a simultaneous integrated boost technique applied with helical Tomotherapy.采用螺旋断层放疗同步整合加量技术对前列腺癌患者进行风险适应性剂量强化术后放疗。
Radiat Oncol. 2017 Aug 10;12(1):125. doi: 10.1186/s13014-017-0862-4.

引用本文的文献

1
Predictive Factors for Gastrointestinal and Genitourinary Toxicities in Prostate Cancer External Beam Radiotherapy: A Scoping Review.前列腺癌外照射放疗中胃肠道和泌尿生殖系统毒性的预测因素:一项范围综述
Diagnostics (Basel). 2025 May 26;15(11):1331. doi: 10.3390/diagnostics15111331.
2
Focal boosted IMRT treatment of prostate cancer to 84 Gy in 28 fractions: preliminary clinical outcomes, toxicity, and dosimetry.前列腺癌的局部增强调强放射治疗,28次分割达84 Gy:初步临床结果、毒性及剂量学
Front Oncol. 2025 May 20;15:1577359. doi: 10.3389/fonc.2025.1577359. eCollection 2025.
3
Cone-beam CT delta-radiomics to predict genitourinary toxicities and international prostate symptom of prostate cancer patients: a pilot study.锥形束 CT 德尔塔放射组学预测前列腺癌患者泌尿生殖系统毒性和国际前列腺症状:一项初步研究。
Sci Rep. 2022 Nov 22;12(1):20136. doi: 10.1038/s41598-022-24435-8.
4
Stereotactic Body Radiation Therapy (SBRT) for Prostate Cancer in Men With a High Baseline International Prostate Symptom Score (IPSS ≥ 15).对基线国际前列腺症状评分较高(IPSS≥15)的男性前列腺癌患者进行立体定向体部放射治疗(SBRT)
Front Oncol. 2020 Jul 3;10:1060. doi: 10.3389/fonc.2020.01060. eCollection 2020.
5
Are all prostate cancer patients "fit" for salvage radiotherapy?所有前列腺癌患者都“适合”挽救性放疗吗?
World J Clin Oncol. 2020 Jan 24;11(1):1-10. doi: 10.5306/wjco.v11.i1.1.
6
Image-guided dose-escalated radiation therapy for localized prostate cancer with helical tomotherapy.螺旋断层放疗引导局部前列腺癌的剂量递增治疗。
Strahlenther Onkol. 2020 Mar;196(3):229-242. doi: 10.1007/s00066-019-01562-2. Epub 2019 Dec 23.
7
Quality of life worsened the most severely in patients immediately after intensity-modulated radiotherapy for prostate cancer.前列腺癌患者在调强放射治疗后,生活质量立即出现最严重的恶化。
Res Rep Urol. 2018 Oct 23;10:169-180. doi: 10.2147/RRU.S168651. eCollection 2018.
8
Comparison of Late Urinary Symptoms Following SBRT and SBRT with IMRT Supplementation for Prostate Cancer.前列腺癌立体定向体部放疗与立体定向体部放疗联合调强适形放疗后的晚期泌尿系统症状比较
Curr Urol. 2018 Jun;11(4):218-224. doi: 10.1159/000447222. Epub 2018 Mar 30.
9
Machine Learning on a Genome-wide Association Study to Predict Late Genitourinary Toxicity After Prostate Radiation Therapy.基于全基因组关联研究的机器学习预测前列腺放射治疗后晚期泌尿生殖系统毒性
Int J Radiat Oncol Biol Phys. 2018 May 1;101(1):128-135. doi: 10.1016/j.ijrobp.2018.01.054. Epub 2018 Jan 31.
10
Prostate cancer treated with reduced-volume intensity-modulated radiation therapy: Report on the 5-year outcome of a prospective series.采用缩野调强放射治疗的前列腺癌:一项前瞻性系列研究的5年结果报告
Medicine (Baltimore). 2017 Dec;96(52):e9450. doi: 10.1097/MD.0000000000009450.

本文引用的文献

1
Long-term survival and toxicity in patients treated with high-dose intensity modulated radiation therapy for localized prostate cancer.高强度调强放疗治疗局限性前列腺癌患者的长期生存和毒性。
Int J Radiat Oncol Biol Phys. 2013 Mar 1;85(3):686-92. doi: 10.1016/j.ijrobp.2012.05.023. Epub 2012 Jul 12.
2
High-dose conformal radiotherapy reduces prostate cancer-specific mortality: results of a meta-analysis.高剂量适形放疗可降低前列腺癌特异性死亡率:荟萃分析结果。
Int J Radiat Oncol Biol Phys. 2012 Aug 1;83(5):e619-25. doi: 10.1016/j.ijrobp.2012.01.051.
3
Incidence and progression of lower urinary tract symptoms in a large prospective cohort of United States men.美国男性大样本前瞻性队列中下尿路症状的发生率和进展情况。
J Urol. 2012 Aug;188(2):496-501. doi: 10.1016/j.juro.2012.03.125. Epub 2012 Jun 15.
4
Functional outcomes and complications following radiation therapy for prostate cancer: a critical analysis of the literature.前列腺癌放射治疗的功能结果和并发症:文献的批判性分析。
Eur Urol. 2012 Jan;61(1):112-27. doi: 10.1016/j.eururo.2011.09.027. Epub 2011 Oct 6.
5
70 Gy versus 80 Gy in localized prostate cancer: 5-year results of GETUG 06 randomized trial.局部前列腺癌 70 Gy 与 80 Gy:GETUG 06 随机试验 5 年结果。
Int J Radiat Oncol Biol Phys. 2011 Jul 15;80(4):1056-63. doi: 10.1016/j.ijrobp.2010.03.049. Epub 2010 Dec 14.
6
EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease.EAU 前列腺癌指南。第 1 部分:局限性疾病的筛查、诊断和治疗。
Eur Urol. 2011 Jan;59(1):61-71. doi: 10.1016/j.eururo.2010.10.039. Epub 2010 Oct 28.
7
External beam radiotherapy for prostate cancer: urinary outcomes for men with high International Prostate Symptom Scores (IPSS).前列腺癌的外照射治疗:国际前列腺症状评分(IPSS)较高的男性的尿控结果。
Int J Radiat Oncol Biol Phys. 2011 Jul 15;80(4):1080-6. doi: 10.1016/j.ijrobp.2010.03.040. Epub 2010 Jul 17.
8
Individualizing quality-of-life outcomes reporting: how localized prostate cancer treatments affect patients with different levels of baseline urinary, bowel, and sexual function.个性化生活质量结果报告:局部前列腺癌治疗如何影响具有不同基线泌尿、肠道和性功能水平的患者。
J Clin Oncol. 2009 Aug 20;27(24):3916-22. doi: 10.1200/JCO.2008.18.6486. Epub 2009 Jul 20.
9
Urinary toxicity after high dose intensity modulated radiotherapy as primary therapy for prostate cancer.高剂量调强放疗作为前列腺癌主要治疗手段后的泌尿毒性
Radiother Oncol. 2009 Jul;92(1):42-7. doi: 10.1016/j.radonc.2009.03.013. Epub 2009 Apr 6.
10
Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer.局限性前列腺癌三维适形放疗和调强放疗后晚期直肠和泌尿系统毒性反应的发生率
Int J Radiat Oncol Biol Phys. 2008 Mar 15;70(4):1124-9. doi: 10.1016/j.ijrobp.2007.11.044.

高强度调强放疗治疗局限性前列腺癌后泌尿生殖毒性改善的模式和预测因素:对定义放疗后尿毒性的影响。

Patterns and predictors of amelioration of genitourinary toxicity after high-dose intensity-modulated radiation therapy for localized prostate cancer: implications for defining postradiotherapy urinary toxicity.

机构信息

Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.

出版信息

Eur Urol. 2013 Dec;64(6):931-8. doi: 10.1016/j.eururo.2013.02.001. Epub 2013 Feb 14.

DOI:10.1016/j.eururo.2013.02.001
PMID:23522772
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4786022/
Abstract

BACKGROUND

Treatment-related toxicity and quality of life (QoL) considerations are important when counseling patients with localized prostate cancer (PCa).

OBJECTIVE

To determine the incidence and longitudinal pattern of late genitourinary (GU) toxicity and QoL after high-dose, intensity-modulated radiotherapy (IMRT).

DESIGN, SETTING, AND PARTICIPANTS: A total of 268 patients with localized PCa were treated between June 2004 and December 2008 at a tertiary referral center. Median follow-up was 5 yr (range: 3-7.7 yr).

INTERVENTION

Patients underwent IMRT to a total dose of 86.4Gy; 50% of patients underwent neoadjuvant and concurrent androgen-deprivation therapy.

OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS

Patients were evaluated with the prospectively obtained International Prostate Symptom Score (IPSS) questionnaire. GU toxicity was also scored using the Common Terminology Criteria for Adverse Events (CTCAE) v.4.0; toxicity events were defined as increase over baseline. Differences in increases in IPSS sums and QoL index between baseline IPSS sum and QoL index groups were analyzed using the Kruskal-Wallis and Mann-Whitney tests. Univariate and multivariate Cox regression models were applied.

RESULTS AND LIMITATIONS

The overall median IPSS sum increase during follow-up was 3 and was less pronounced among patients with severe baseline symptoms compared with those with mild baseline symptoms (median increase: 0 vs 4; p<0.0001). Overall QoL index was unchanged after IMRT but appeared to improve in patients with dissatisfied baseline QoL compared with satisfied baseline QoL (p<0.0001). Fifty-five (20%) and 2 (1%) patients developed grade 2 and 3 late GU toxicities, respectively; however, in 28 of 57 patients (49%), toxicity resolved during follow-up. Even though the IPSS data were prospectively obtained, most patients were not treated within a prospective protocol.

CONCLUSIONS

Late GU toxicity after high-dose IMRT was mild; severe, late GU toxicity was rare. Changes in IPSS sum and QoL index were dependent on the baseline GU function, which might be useful for future patient counseling.

摘要

背景

在为局限性前列腺癌(PCa)患者提供咨询时,需要考虑与治疗相关的毒性和生活质量(QoL)。

目的

确定高强度调强放疗(IMRT)后晚期泌尿生殖系统(GU)毒性和 QoL 的发生和纵向模式。

设计、地点和参与者:共 268 例局限性 PCa 患者于 2004 年 6 月至 2008 年 12 月在一家三级转诊中心接受治疗。中位随访时间为 5 年(范围:3-7.7 年)。

干预

患者接受 86.4Gy 的 IMRT 总剂量;50%的患者接受新辅助和同步雄激素剥夺治疗。

观察指标和统计分析

患者采用前瞻性获得的国际前列腺症状评分(IPSS)问卷进行评估。GU 毒性也采用不良事件常用术语标准(CTCAE)v.4.0 进行评分;毒性事件定义为较基线增加。采用 Kruskal-Wallis 和 Mann-Whitney 检验分析基线 IPSS 总和 QoL 指数组之间 IPSS 总和和 QoL 指数增加的差异。应用单变量和多变量 Cox 回归模型。

结果和局限性

随访期间总体中位 IPSS 总和增加 3 分,基线症状严重的患者增加幅度小于基线症状轻微的患者(中位增加:0 分与 4 分;p<0.0001)。IMRT 后总体 QoL 指数保持不变,但与基线 QoL 满意度相比,基线 QoL 不满意的患者似乎有所改善(p<0.0001)。55 例(20%)和 2 例(1%)患者分别发生 2 级和 3 级晚期 GU 毒性,但在 57 例患者中有 28 例(49%)毒性在随访期间得到缓解。尽管 IPSS 数据是前瞻性获得的,但大多数患者并未按前瞻性方案进行治疗。

结论

高剂量 IMRT 后晚期 GU 毒性较轻;严重的晚期 GU 毒性罕见。IPSS 总和和 QoL 指数的变化取决于基线 GU 功能,这可能对未来的患者咨询有用。